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Abstract
Introduction: Autoimmune thyroid diseases, including Graves’ and Hashimoto’s thyroiditis, are the most frequent autoimmune disorders. 
Viral infection, including Epstein-Barr virus (EBV), is one of the most frequently considered environmental factors involved in autoim-
munity. Its role in the development of AITD has not been confirmed so far. 
Material and methods: Surgical specimens of Graves’ and Hashimoto’s diseases and nodular goitres were included in the study. The ex-
pression of EBV latent membrane protein 1 (LMP1) was analysed by immunohistochemistry, with the parallel detection of virus-encoded 
small nuclear non-polyadenylated RNAs (EBER) by in situ hybridisation.
Results: In none of the Graves’ disease specimens but in 34.5% of Hashimoto’s thyroiditis cases the cytoplasmic expression of LMP1 
was detected in follicular epithelial cells and in infiltrating lymphocytes. EBER nuclear expression was detected in 80.7% of Hashimoto’s 
thyroiditis cases and 62.5% of Graves´ disease cases, with positive correlation between LMP1 and EBER positivity in all Hashimoto’s 
thyroiditis LMP1-positive cases. 
Conclusions: We assume that high prevalence of EBV infection in cases of Hashimoto’s and Graves’ diseases imply a potential aetiological 
role of EBV in autoimmune thyroiditis. The initiation of autoimmune thyroiditis could start with EBV latency type III infection of follicular 
epithelium characterised by LMP1 expression involving the production of inflammatory mediators leading to recruitment of lymphocytes. 
The EBV positivity of the infiltrating lymphocytes could be only the presentation of a carrier state, but in cases with EBER+/ LMP1+ 
lymphocytes (transforming latent infection) it could represent a negative prognostic marker pointing to a higher risk of primary thyroid 
lymphoma development. (Endokrynol Pol 2015; 66 (2): 132–136)
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Streszczenie
Wstęp: Autoimmunologiczne choroby taczycy, w tym zapalenia tarczycy Graves’a i Hashimoto, są najczęstszymi zaburzeniami autoimmu-
nologicznymi. Infekcja wirusowa, w tym wirusem Epstein-Barr’a (EBV), jest jednym z najczęściej rozważanych czynników środowiskowych 
łączonych z autoimmunologią. Jego rola w rozwoju autoimmunologicznyh chorób taczycy (AITD) nie została do tej pory potwierdzona.
Materiały i metody: Zbadano chirurgicznie pobrane preparaty od chorych na chorobę Gravesa, chorobę Hashimoto i wole guzowate. 
Ekspresja latentnego białka błonowego 1 (LMP1) EBV była zanalizowana metodami immunohistochemicznymi, z równoczesnym wykry-
waniem kodowanych wirusem, małych, jądrzastych, niespoliadenylowanych RNA (EBER) poprzez hybrydazcję in situ.
Wyniki: W żadnym z przypadków choroby Gravesa nie stwierdzono w komórkach pęcherzykowych i naciekających limfocytach eks-
presji LMP1w cytoplazmie, ale wykryto ją w 34,5% przypadkach choroby Hashimoto. Jądrowa ekspresja EBER została wykryta w 80,7% 
przypadków zapalenia tarczycy Hashimoto i w 62,5% choroby Gravesa. Zauważono również dodatnią korelację pomiędzy LMP1 i wy-
stępowaniem EBER we wszystkich przypadkach choroby Hashimoto LMP1+.
Wnioski: Autorzy uwazają, że powszechne występowanie infekcji EBV w chorobach Hashimoto i Gravesa sugeruje potencjalną rolą etio-
logiczną EBV w rozwoju autoimmunologicznych zapaleń tarczycy. Zapoczątkowaniem autoimmunologicznych zapaleń tarczycy może być 
utajona infekcja EBV typu III, charakteryzująca się ekspresją LMP1 w komórkach pęcherzykowych i związana z produkcją mediatorów 
zapalnych prowadzącą do migracji limfocytów. Obecność EBV w naciekach limfocytarnych może być jedynie charakterystyczna dla no-
siciela wirusa ale w przypadku obecności limfocytów EBER+/LMP1+ (przekształcajcych infekcję utajoną) może być negatywnym mar-
kerem prognostycznym wskazując podwyższone ryzyko rozwoju pierwotnego chłoniaka tarczycy. (Endokrynol Pol 2015; 66 (2): 132–136)
Słowa kluczowe: Choroba Gravesa; zapalenie tarczycy typu Hashimoto; infekcje wirusem Epsterin-Barra
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Introduction
Autoimmune thyroid diseases (AITD), including 
Graves’ disease and Hashimoto’s thyroiditis, afflict 
up to 10% of the world population [1]. Their aetiology 
remains unclear at present but it is generally believed 
that both genetic and environmental factors contribute 
to their development [2]. Viral infections are frequently 
cited as a major environmental factor involved in the 
pathogenesis of autoimmune processes. 
The Epstein-Barr virus (EBV) is a double-stranded 
DNA virus, a member of the herpes virus family [3]. 
Approximately 95% of the world’s adult population is 
infected during life and become lifelong carriers. Pri-
mary infection by EBV causes quite a different course 
of the disease depending on the age of the patient [4]. 
EBV infection is associated with the development of 
a variety of lymphoid and epithelial tumours and 
post-transplant lymphoproliferative disorders [5–7]. 
EBV infection is also known to be involved in the de-
velopment of different autoimmune diseases. Several 
studies brought evidence for the connection of EBV in-
fection and multiple sclerosis [8, 9] and even suggested 
a prognostic role of elevated anti-EBV antibody titres 
in MS development [10]. Toussirot et al. demonstrated 
serological differences in patients with systemic lupus 
erythematodes and rheumatoid arthritis in comparison 
to healthy controls, and confirmed the presence of viral 
DNA and RNA in disease targeted tissue in patients 
with rheumatoid arthritis and Sjögren syndrome [11]. 
AITDs have also been shown to be associated with 
a variety of infectious agents, including EBV [12]. Most 
of these data are only indirect epidemiological and 
serological indications [13] and they do not prove the 
pathogens causality. Considering the limited direct 
evidence, the present study focused on direct EBV 
detection in the thyroid tissue from patients with au-
toimmune thyroid gland diseases.
Material and methods
Archival formalin fixed in paraffin embedded speci-
mens from therapeutic and diagnostic thyroidectomies, 
including the diagnosis of Hashimoto’s thyroiditis 
(n = 26), Graves’ disease (n = 8), and nodular goitres 
(n = 8) as controls, were used for analysis. The samples 
were evaluated and classified on the basis of published 
histopathological criteria [14].
Immunohistochemistry
For the immunohistochemical detection of EBV infected 
cells, antibodies against the viral latent membrane 
protein 1 (LMP1) were used. Two different primary 
antibodies were tested: monoclonal mouse anti-LMP 
protein (clone CS.1-4, Dako, Denmark) and monoclonal 
mouse anti-LMP Ab-1 protein (clone CS.1-4, Labvision, 
USA). Deparaffinisation was followed by seven minutes 
of proteinase K-induced epitope retrieval. Afterwards, 
the sections were incubated first with primary antibod-
ies for 60 minutes at room temperature and then for 
30 minutes with the secondary antibody (Envision, 
Dako, Denmark). Visualisation of the antigen site was 
achieved by 3, 3’-diaminobenzidine (Dako).
In situ hybridisation
The fluorescein-conjugated EBV Probe ISH Kit (Vec-
tor Laboratories, USA) was used for the detection of 
virus-encoded small nuclear non-polyadenylated 
RNAs (EBER) in the latently infected cells. The 5-µm 
thick tissue sections were incubated with the probe 
for 2 hours at 37°C, followed by 10 minutes incubation 
with blocking solution (rabbit serum diluted 1:5 in Tris 
buffered saline — TBS, containing 3% bovine albumin) 
and 30 minutes incubation with rabbit anti-fluorescein 
secondary antibody conjugated with alkaline phos-
phatase diluted 1:200 in TBS. The alkaline phosphatase 
activity was visualised by overnight incubation with 
the enzyme substrate diluted 1:50 in substrate buffer 
with the inhibitor of endogenic phosphatase activity 
(levamisole hydrochloride) diluted 1:1000. The slides 
were counterstained with nuclear red.
Samples, incubated without addition of primary 
antibody or the EBV probe, were used as negative con-
trols. The expression of both viral LMP1 and EBER were 
evaluated by optical microscope. Only cytoplasmic 
LMP1 expression and nuclear EBER expression were 
considered positive. 
Results
Immunohistochemical EBV positivity was demon-
strated only in samples of Hashimoto’s thyroiditis. In 
8 of 26 (34.5%) Hashimoto’s thyroiditis cases there was 
cytoplasmic expression of viral latent membrane protein 
1 (LMP1) in follicular epithelial cells and in infiltrating 
lymphocytes (Fig. 1). Graves’ disease specimens and 
control goitres were negative for LMP1. Antibodies 
from both manufacturers gave comparable intensity 
of positivity and expression pattern of LMP1; negative 
control samples showed no positivity.
The detection of EBV-positive cells with the use of in 
situ hybridisation method (detection of EBER) showed 
nuclear expression in 21 of 24 Hashimoto’s thyroiditis 
cases (80.7%) and in 5 of 8 Graves’ disease cases (62.5%). 
Samples of Hashimoto’s thyroiditis demonstrated focal 
to diffuse positivity, mainly of infiltrating lymphocytes. 
In the areas with lymphatic follicles predominantly 
the mantle zone and interfollicular lymphocytes were 
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positive (Fig. 2). In three cases positivity of epithelial 
cells predominated. Samples of Graves’ disease dem-
onstrated EBER expression predominantly in follicular 
epithelial cells (Fig. 3). All negative control samples 
lacked EBER positivity.
Positive correlation was found between LMP1 
immunohistochemical positivity and EBER in situ hy-
bridisation results in all eight Hashimoto’s thyroiditis 
LMP1 positive cases.
Discussion
The causative role of infectious agents represents an 
attractive hypothesis in the development of autoim-
mune diseases. Indirect epidemiological and serologi-
cal data indicate the involvement of infectious agents 
in the initiation and/or progression of autoimmune 
processes [13]. 
Epstein-Barr virus is a widespread human herpes 
virus mostly causing latent asymptomatic infection; 
however, it is also associated with several neoplastic 
diseases. There is also increasing evidence of its connec-
tion with autoimmune diseases. According to Toussirot 
[11], EBV fulfils all criteria for a causal factor of auto-
immunity, including the worldwide prevalence, the 
autoimmunity preceding infection, and the capability 
to modify the host’s immune response. Despite of lack 
of clear confirmation of an etiopathogenic role of EBV 
Figure 3. EBV in Grave’s thyroiditis. In situ hybridisation 
reaction with virus-encoded small nuclear non-polyadenylated 
RNAs (EBER) showed EBV presence in the nuclei of follicular 
cells (arrow). EBER, 400×
Rycina 3. EBV w zapaleniu tarczycy Gravesa. Reakcja hybry-
dyzacji in situ z kodowanymi wirusowymi, małymi, jądrzastymi, 
niespoliadenylowanymi RNA (EBER) potwierdziła obecność EBV 
w jądrach komórek ziarnistych (strzałka). EBER, 400×
Figure 1. LMP1 expression in Hashimoto’s thyroiditis. 
Immunohistochemical reaction with cytoplasmic latent membrane 
protein 1 (LMP1) positivity showed EBV presence in follicular 
epithelial cells (open arrow) and in infiltrating lymphocytes 
(arrow). Avidin–biotin–peroxidase, diaminobenzidine, 400×
Rycina 1. Ekspesja LMP1 w zapaleniu tarczycy Hashimoto. 
Reakcja immunohistochemiczna z cytoplazmatycznym latentym 
białkiem błonowym 1 (LMP1) uwidoczniła obecność EBV 
w komórkach pęcherzykowych (pusta strzałka) i w naciekających 
limfocytach (strzałka). Awidyna–biotyna– peroksydaza, 
diaminobenzydyna, 400×
Figure 2. EBV in lymphocytic infiltration in Hashimoto’s 
thyroiditis. In situ hybridisation reaction with virus-encoded small 
nuclear non-polyadenylated RNAs (EBER) showed EBV presence 
in the nuclei of infiltrating lymphocytes (arrow) and in nuclei of 
follicular cells (open arrow). EBER, 150×
Rycina 2. EBV w limfatycznej infiltracji w zapaleniu tarczycy 
Haschimoto. Reakcja hybrydyzacji in situ z kodowanymi 
wirusowymi, małymi jądrzastym, niespoliadenylowanymi RNA 
(EBER) potwierdziło obecność EBV w jądrach infiltrujących 
limfocyty (strzałka) i w jądrach komórek ziarnistych (pusta 
strzałka). EBER, 150×
in autoimmune processes, some studies have already 
proven the presence of viral genes in disease affected 
tissues and organs [11, 15, 16]. 
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Our study demonstrated the presence of EBV in 
the thyroid gland tissues affected by autoimmune 
thyroiditis. Evaluation of viral nuclear RNA (EBER) 
positivity pointed to a high prevalence of EBV in cases 
of Hashimito´s thyroiditis (80.7%) as well as in Grave’s 
disease (62.5%). On the contrary, none of the control 
goitres demonstrated EBER expression. The question is 
whether this high occurrence of EBV in thyroid gland 
samples is associated directly with autoimmune disease 
development or if it is the result of the high EBV carrier 
rate in the population. The absence of EBV in all control 
goitres observed in our study favours the first possibil-
ity. An analogical attempt to map the herpes simplex 
1 and 2, CMV and human herpes virus type 6 and 
7 infection in tissue samples of AITDs did not provide 
any conclusive connections [16].
The main target cells for EBV are B lymphocytes, 
but the virus can infect also T lymphocytes and epi-
thelial cells [17]. The present study demonstrates the 
expression of EBV-associated products in infiltrating 
lymphocytes in Hashimoto’s thyroiditis and in thyroid 
follicular cells in cases of Hashimoto’s thyroiditis and 
Grave’s disease. 
EBV infects cells in latent or lytic forms. Latently 
infected cells generally show different gene expression 
patterns. In latency type I, or resting state, only EBV 
nuclear antigen 1 (EBNA-1) and two small polyade-
nylated nuclear RNAs (EBER 1 and 2) are expressed, as 
typically found in Burkitt’s lymphoma cells. In latency 
type II additional expression of three latent membrane 
proteins, LMP-1, LMP-2A, and LMP-2B is observed, as 
described in Hodgkin’s disease and the nasopharyngeal 
carcinoma. Latency type III (continuously proliferating 
state) is seen in lymphoproliferative diseases arising in 
EBV-transformed lymphoblastoid cells in immunocom-
promised individuals. In this group all six EBNAs, all 
three LMPs, and the two EBERs are expressed. Latency 
type IV is found in patients with infectious mononu-
cleosis and with post-transplant lymphoproliferative 
disease [17]. 
The immunohistochemically detected latent mem-
brane protein traced in 8 of 24 Hashimoto’s thyroiditis 
cases is associated with latent viral infection and is 
characteristic for latency type II and III, but not for la-
tency type I [18]. In contrast to LMP1, EBER, detected 
in 21 of 24 Hashimoto’s thyroiditis and in 5 of 8 cases 
of Graves’ disease, is expressed in all types of latent 
EBV infection. These findings allow us to identify 
two groups of patients with Hashimoto’s thyroiditis: 
EBER+/LMP1– cases characterising a type I latency or 
resting EBV infection, whereas EBER+/LMP1+ samples 
represent a latency type II or III. Type III latent EBV 
infection is referred to as proliferating or transforming 
state. Considering the morphological characteristics of 
Hashimoto’s thyroiditis samples (high percentage of 
infiltrating lymphocytes, lymphatic follicles formation, 
fibrosis, etc.) most of the LMP1+ cases showed only 
a low number of lymphocytes, characteristic for an early 
stage of autoimmunity. In these cases there was also 
a more pronounced LMP1 positivity in the follicular 
epithelium. LMP1 is a viral mimic of CD40, a costimula-
tory protein found on antigen-presenting cells with the 
function of an activating receptor of various immune 
cells, mainly B lymphocytes. Thus, LMP1 signalling 
to B cells lacks regulatory control, allowing LMP1 to 
activate B lymphocytes in an abnormal manner that 
can contribute to the pathogenesis of human B-cell 
lymphoma and autoimmune disease [19, 20]. 
It is believed that a long-lasting chronic inflamma-
tory irritation in autoimmune states could be the patho-
genic basis for development of malignant tumours. 
More than 90% of all primary thyroid lymphomas 
develop in patients with a history of Hashimoto´s dis-
ease [21]. The majority of these lymphomas are of B cell 
origin. EBV has the ability to transform normal resting 
B cells in vitro to proliferating lymphoblasts. This EBV-
induced transformation is connected to type III latent 
infection [17]. Determining the latency type could in 
these cases have a potential prognostic value separat-
ing Hashimoto’s disease patients with a higher risk for 
malignant lymphoma development. The main lym-
phoma types occurring in patients with Hashimoto’s 
disease are diffuse large B-cell lymphoma (DLBCL) and 
mucosa-associated lymphoid tissue (MALT) lymphomas 
[21]. A direct link to EBV infection in these lymphomas 
has not yet been clearly established. The distinction of 
a new subtype of DLBCL, EBV-positive DLBCL of the 
elderly, indicates that at least a subset of these lympho-
mas is associated with EBV [22].
EBV also plays an etiopathogenic role in several 
epithelial malignancies, foremost nasopharyngeal car-
cinoma. Hannigan et al. [23] have demonstrated that 
the transgenic expression of EBV latent membrane 
protein 1 induces different changes in epithelial tissue, 
including not only proliferation, but also production 
of inflammatory cytokines and chemokines. Accord-
ingly, EBV infection of follicular epithelial cells could 
contribute to the recruitment of inflammatory cells in 
autoimmune thyroiditis. 
In summary, we demonstrated a high prevalence of 
EBV infection in cases of Hashimito’s thyroiditis (80.7%) 
as well as in samples of Graves’ disease (62.5%). The 
results of the presented study may be partially influ-
enced by the limited amount of the analyzed samples. 
Nevertheless, the present findings could imply a criti-
cal etiopathogenic role of EBV in autoimmune thyroid 
disease. The initiation of EBV-linked autoimmune 
thyroiditis could start with changes in the follicular 
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epithelium caused by transforming latency type III 
EBV infection characterised by LMP1 expression. These 
epithelial changes may also involve the production of 
inflammatory mediators leading to the recruitment 
of lymphocytes. The EBV positivity of the infiltrating 
lymphocytes could be only the presentation of a carrier 
state, but at least in cases with EBER+/ LMP1+ lym-
phocytes — transforming latent infection — it could be 
a negative prognostic marker pointing to a higher risk 
of primary thyroid lymphoma development. 
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